QuidelOrtho (NASDAQ:QDEL) Reaches New 1-Year Low - Here's What Happened

QuidelOrtho logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • QuidelOrtho hit a new 52-week low, trading as low as $9.82 and last quoted at $9.967, down from its prior close of $10.21.
  • Quarterly EPS of $0.31 beat estimates of $0.18, but revenue of $618.9 million missed forecasts and fell 11.6% year over year.
  • Analyst sentiment remains cautious: four analysts rate the shares Hold and two rate them Sell, for an overall “Reduce” rating and an average price target of $13.62.
  • Five stocks to consider instead of QuidelOrtho.

QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report)'s share price reached a new 52-week low during trading on Tuesday. The company traded as low as $9.82 and last traded at $9.9670, with a volume of 994,067 shares traded. The stock had previously closed at $10.21.

Analyst Ratings Changes

Several analysts recently weighed in on QDEL shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of QuidelOrtho in a research note on Thursday, October 15th. Zacks Research upgraded QuidelOrtho from a "strong sell" rating to a "hold" rating in a research report on Friday, October 9th. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, QuidelOrtho has an average rating of "Reduce" and an average target price of $13.62.

Read Our Latest Stock Analysis on QuidelOrtho

QuidelOrtho Price Performance

The company has a debt-to-equity ratio of 1.40, a current ratio of 1.36 and a quick ratio of 0.75. The stock has a market cap of $677.18 million, a price-to-earnings ratio of -1.82 and a beta of 0.77. The business's 50-day simple moving average is $12.23 and its two-hundred day simple moving average is $15.44.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.13. QuidelOrtho had a negative net margin of 14.24% and a positive return on equity of 3.22%. The company had revenue of $618.90 million during the quarter, compared to the consensus estimate of $627.83 million. During the same period in the prior year, the business earned $0.80 earnings per share. The company's revenue for the quarter was down 11.6% compared to the same quarter last year. Research analysts expect that QuidelOrtho Corporation will post 0.66 earnings per share for the current year.

Hedge Funds Weigh In On QuidelOrtho

A number of institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of QuidelOrtho by 67.7% during the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company's stock valued at $38,000 after purchasing an additional 882 shares in the last quarter. IFP Advisors Inc grew its holdings in shares of QuidelOrtho by 14,166.7% during the second quarter. IFP Advisors Inc now owns 2,568 shares of the company's stock worth $45,000 after purchasing an additional 2,550 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of QuidelOrtho by 111.3% in the third quarter. Global Retirement Partners LLC now owns 2,628 shares of the company's stock valued at $28,000 after buying an additional 1,384 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of QuidelOrtho in the second quarter valued at approximately $53,000. Finally, Allworth Financial LP acquired a new position in shares of QuidelOrtho in the second quarter valued at approximately $56,000. Institutional investors and hedge funds own 99.00% of the company's stock.

About QuidelOrtho

(Get Free Report)

QuidelOrtho Corporation develops and manufactures diagnostic testing products used in healthcare settings. Its offerings include tests and instruments for immunoassay, molecular diagnostics, clinical chemistry, and transfusion medicine, as well as rapid tests designed for point-of-care use. The company serves hospitals, clinical laboratories, blood banks, physician offices, and other healthcare providers. Its product lines include the VITROS clinical laboratory systems, ORTHO VISION blood-bank analyzers, and Sofia rapid diagnostic platforms.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in QuidelOrtho Right Now?

Before you consider QuidelOrtho, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.

While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines